Acorda's multiple sclerosis drug faces generic threat
June 26 Thu Jun 26, 2014
(Reuters) - Acorda Therapeutics Inc said Actavis Plc plans to market a generic version of Acorda's multiple sclerosis treatment, Ampyra.
Ampyra, which was approved in January 2010, had net sales of $72.5 million in the first quarter ended March 31.
Acorda said Actavis has submitted a marketing approval application with the U.S. Food and Drug Administration for a generic version of the drug.
Acorda said it intends to vigorously defend its intellectual property rights.
(Reporting By Penumudi Amrutha; Editing by Sriraj Kalluvila)
Link: http://www.reuters.com/article/2014/06/26/acorda-therapeut-drugs-idUSL4N0P72PD20140626
No comments:
Post a Comment